摘要
背景：维多珠单抗对术后并发症增加的单独作用仍存在争议，类似于有关抗TNF和术后并发症的争议数据。 目的：确定维多珠单抗术后并发症的风险。 方法：对迄今有关比较用维多珠单抗治疗和未用维多珠单抗治疗的患者的术后结局进行比较的文献进行综述。研究按所有炎症性肠病合并在一起的研究进行了分层，专门针对克罗恩病或溃疡性结肠炎的研究，以及仅包括儿科患者的研究。 结果：关于维多珠单抗和术后并发症增加的相关数据，在成人和儿童文献中仍存在争议。在克罗恩病文献中似乎发现维多珠单抗与术后感染并发症风险增加之间的最强关联。 结论：维多珠单抗可能与克罗恩病的术后感染并发症风险增加有关，但由于难以分离单独使用生物制剂的慢性病患者，异质患者群体（包括多种糖皮质激素在内的多种药物）的疗效，因此文献仍存在争议。
关键词: 维多珠单抗，肠炎，手术干预，术后感染性并发症，腹内败血症，克罗恩病，溃疡性结肠炎。
图形摘要
[1]
Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2017; 66(5): 839-51.
[2]
Dave M, Purohit T, Razonable R, Loftus EV Jr. Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis 2014; 20(1): 196-212.
[3]
Alves A, Panis Y, Bouhnik Y, et al. Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn’s disease: a multivariate analysis in 161 consecutive patients. Dis Colon Rectum 2007; 50(3): 331-6.
[4]
Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients. J Gastrointest Surg 2008; 12(10): 1738-44.
[5]
Bafford AC, Powers S, Ha C, et al. Immunosuppressive therapy does not increase operative morbidity in patients with Crohn’s disease. J Clin Gastroenterol 2013; 47(6): 491-5.
[6]
Billioud V, Ford AC, Tedesco ED, et al. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. J Crohn’s Colitis 2013; 7(11): 853-67.
[7]
Bregnbak D, Mortensen C, Bendtsen F. Infliximab and complications after colectomy in patients with ulcerative colitis. J Crohns Colitis 2012; 6(3): 281-6.
[8]
Brouquet A, Maggiori L, Zerbib P, et al. Anti-TNF therapy is associated with an increased risk of postoperative morbidity after surgery for ileocolonic crohn disease: results of a prospective nationwide cohort. Ann Surg 2018; 267(2): 221-8.
[9]
de Buck van Overstraeten A, Eshuis EJ, Vermeire S, et al. Short- and medium-term outcomes following primary ileocaecal resection for Crohn’s disease in two specialist centres. Br J Surg 2017; 104(12): 1713-22.
[10]
Eshuis EJ, Al Saady RL, Stokkers PC, et al. Previous infliximab therapy and postoperative complications after proctocolectomy with ileum pouch anal anastomosis. J Crohn’s Colitis 2013; 7(2): 142-9.
[11]
Fumery M, Seksik P, Auzolle C, et al. Postoperative complications after ileocecal resection in crohn’s disease: a prospective study from the remind group. Am J Gastroenterol 2017; 112(2): 337-45.
[12]
Indar AA, Young-Fadok TM, Heppell J, Efron JE. Effect of perioperative immunosuppressive medication on early outcome in Crohn’s disease patients. World J Surg 2009; 33(5): 1049-52.
[13]
Kopylov U, Ben-Horin S, Zmora O, Eliakim R, Katz LH. Anti-tumor necrosis factor and postoperative complications in Crohn’s disease: systematic review and meta-analysis. Inflamm Bowel Dis 2012; 18(12): 2404-13.
[14]
Morar PS, Hodgkinson JD, Thalayasingam S, et al. Determining predictors for intra-abdominal septic complications following ileocolonic resection for crohn’s disease-considerations in pre-operative and peri-operative optimisation techniques to improve outcome. J Crohn’s Colitis 2015; 9(6): 483-91.
[15]
Rizzo G, Armuzzi A, Pugliese D, et al. Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. Int J Colorectal Dis 2011; 26(11): 1435-44.
[16]
Lightner AL, Raffals LE, Mathis KL, et al. Postoperative outcomes in vedolizumab-treated patients undergoing abdominal operations for inflammatory bowel disease. J Crohn’s Colitis 2017; 11(2): 185-90.
[17]
Lightner AL, Mathis KL, Tse CS, et al. Postoperative outcomes in vedolizumab-treated patients undergoing major abdominal operations for inflammatory bowel disease: Retrospective multicenter cohort study. Inflamm Bowel Dis 2018; 24: 871-6.
[18]
Yamada A, Komaki Y, Patel N, et al. Risk of postoperative complications among inflammatory bowel disease patients treated preoperatively with vedolizumab. Am J Gastroenterol 2017; 112(9): 1423-9.
[19]
Koh S, Zaghiyan K, Fleshner P. Safety and efficacy of the perioperative use of vedolizumab in medically refractory IBD patients. Does "gut-specificity" impact surgical morbidity? American
Society of Cataract and Refractive Surgery/American Society of
Ophthalmic Administrators (ASCRS/ASOA) annual meeting; April 30-May 4, 2016. Los Angeles, CA
[20]
Schils N, De Buck van Overstraeten A, Vermeire S, et al. Perioperative use of vedolizumab seems not associated with short-term postoperative infectious complications in patients with Crohn’s disease undergoing right hemicolectomy with ileocolonic anastomosis. 12th Congress of European Crohn’s and Colitis Organizationi (ECCO). February 15-18, 2017; Barcelona, Spain.
[21]
Lightner AL, McKenna NP, Tse CS, et al. Postoperative outcomes in vedolizumab-treated Crohn’s disease patients undergoing major abdominal operations. Aliment Pharmacol Ther 2018; 47: 573-80.
[22]
Ferrante M, de Buck van Overstraeten A, Schils N, et al. Perioperative use of vedolizumab is not associated with postoperative infectious complications in patients with ulcerative colitis undergoing colectomy. J Crohn’s Colitis 2017; 11(11): 1353-61.
[23]
Lightner AL, McKenna NP, Moncrief S, et al. Surgical outcomes in vedolizumab-treated patients with ulcerative colitis. Inflamm Bowel Dis 2017; 23(12): 2197-201.
[24]
Kiely JM, Fazio VW, Remzi FH, Shen B, Kiran RP. Pelvic sepsis after IPAA adversely affects function of the pouch and quality of life. Dis Colon Rectum 2012; 55(4): 387-92.
[25]
Papamichael K, Chachu KA, Vajravelu RK, et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. Clin Gastroenterol Hepatol 2017; 15(10) 1580-8 e3
[26]
Ungar B, Levy I, Yavne Y, et al. Optimizing anti-tnf-alpha therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2016; 14(4) 550-7 e2.
[27]
Ungar B, Kopylov U, Yavzori M, et al. Association of vedolizumab level, anti-drug antibodies, and alpha4beta7 occupancy with response in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2018; 16(5): 697-705. e7
[28]
Yacoub W, Williet N, Pouillon L, et al. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Aliment Pharmacol Ther 2018; 47(7): 906-12.
[29]
Dreesen E, Verstockt B, Bian S, et al. Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2018; 16(12): 1937-46. e8
[30]
Al Bawardy B, Piovezani Ramos G, Willrich MAV, et al. Clinical experience with vedolizumab trough levels in inflammatory bowel disease. Gastroenterol 2018; 154(6): S821-22.
[31]
Rosario M, Wyant T, Leach T, et al. Vedolizumab pharmacokinetics, pharmacodynamics, safety, and tolerability following administration of a single, ascending, intravenous dose to healthy volunteers. Clin Drug Investig 2016; 36(11): 913-23.
[32]
Lau C, Dubinsky M, Melmed G, et al. The impact of preoperative serum anti-TNFalpha therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg 2015; 261(3): 487-96.
[33]
Zimmerman LA, Zalieckas JM, Shamberger RC, Bousvaros A. Postoperative complications of pediatric patients with inflammatory bowel disease treated with vedolizumab. J Pediatr Surg 2018; 53(7): 1330-3.
Article Metrics
59
2